Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
7.68
-0.32 (-4.00%)
At close: Dec 5, 2025, 4:00 PM EST
7.76
+0.08 (1.04%)
After-hours: Dec 5, 2025, 6:28 PM EST
Relay Therapeutics Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Relay Therapeutics stock ranges from a low of $6.00 to a high of $23. The average analyst price target of $16 forecasts a 108.33% increase in the stock price over the next year.
Price Target: $16.00 (+108.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Relay Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 8 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 13 | 13 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $4 → $6 | Hold | Maintains | $4 → $6 | -21.87% | Nov 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +95.31% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +82.29% | Aug 26, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $29 → $19 | Strong Buy | Maintains | $29 → $19 | +147.40% | Aug 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $30 → $10 | Strong Buy | Maintains | $30 → $10 | +30.21% | May 7, 2025 |
Financial Forecast
Revenue This Year
12.06M
from 10.01M
Increased by 20.47%
Revenue Next Year
8.08M
from 12.06M
Decreased by -32.94%
EPS This Year
-1.77
from -2.36
EPS Next Year
-1.69
from -1.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 40.3M | 42.2M | ||||
| Avg | 12.1M | 8.1M | ||||
| Low | 7.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 302.9% | 250.1% | ||||
| Avg | 20.5% | -32.9% | ||||
| Low | -21.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.58 | -1.41 | ||||
| Avg | -1.77 | -1.69 | ||||
| Low | -2.04 | -2.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.